In Vivo Efficacy of Humanized WCK 5222 (Cefepime-Zidebactam) Exposures against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Thigh Model | Zendy

Safa S. Almarzoky Abuhussain | Zendy; Lindsay M. Avery | Zendy; Kamilia Abdelraouf | Zendy; David P. Nicolau | Zendy

Open Access

In Vivo Efficacy of Humanized WCK 5222 (Cefepime-Zidebactam) Exposures against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Thigh Model

Author(s) -

Safa S. Almarzoky Abuhussain,

Lindsay M. Avery,

Kamilia Abdelraouf,

David P. Nicolau

Publication year - 2018

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01931-18

Subject(s) - cefepime , acinetobacter baumannii , in vivo , medicine , acinetobacter , microbiology and biotechnology , meropenem , antibiotics , biology , imipenem , pseudomonas aeruginosa , antibiotic resistance , bacteria , genetics

Herein, we describe thein vivo efficacy of human-simulated WCK 5222 (cefepime-zidebactam) exposure against carbapenem-resistantAcinetobacter baumannii strains in a neutropenic murine thigh infection model. Five of the six isolates examined expressed OXA-23 or OXA-24.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research